APA (7th ed.) Citation

AJ, S., KV, K., NS, R., NT, P., C, A., Z, H., & JS, B. (2024). Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence. Hepatology communications, 8(6), . https://doi.org/10.1097/HC9.0000000000000436

Chicago Style (17th ed.) Citation

AJ, Sanyal, Kowdley KV, Reau NS, Pyrsopoulos NT, Allen C, Heimanson Z, and Bajaj JS. "Rifaximin Plus Lactulose Versus Lactulose Alone for Reducing the Risk of HE Recurrence." Hepatology Communications 8, no. 6 (2024). https://doi.org/10.1097/HC9.0000000000000436.

MLA (9th ed.) Citation

AJ, Sanyal, et al. "Rifaximin Plus Lactulose Versus Lactulose Alone for Reducing the Risk of HE Recurrence." Hepatology Communications, vol. 8, no. 6, 2024, https://doi.org/10.1097/HC9.0000000000000436.